Align Financial LLC Makes New Investment in Stryker Corporation $SYK

Align Financial LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 64,724 shares of the medical technology company’s stock, valued at approximately $22,749,000.

Several other hedge funds have also recently added to or reduced their stakes in SYK. Norges Bank bought a new stake in Stryker during the fourth quarter worth about $1,822,272,000. Corient Private Wealth LLC lifted its stake in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Strive Asset Management LLC bought a new stake in Stryker during the third quarter worth about $227,389,000. Finally, Credit Agricole S A bought a new stake in Stryker during the third quarter worth about $194,045,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 3.0%

Shares of NYSE:SYK opened at $301.24 on Thursday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The stock’s 50-day moving average is $314.89 and its 200 day moving average is $342.38. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market cap of $115.48 billion, a PE ratio of 34.87, a P/E/G ratio of 1.99 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the company posted $2.84 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio is 40.74%.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. UBS Group decreased their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Canaccord Genuity Group decreased their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Evercore set a $355.00 price objective on Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.